Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (Nature Medicine, (2021), 27, 2, (279-288), 10.1038/s41591-020-01179-4)

9Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the version of this article initially published, the numbers of cells in the third sentence of the second paragraph of the Methods subsection ‘Antibody-dependent neutrophil phagocytosis’ (500,000) and in the fifth sentence of the first paragraph of the Methods subsection ‘Antibody-dependent monocyte phagocytosis’ (250,000) were incorrect. The correct numbers are 50,000 and 25,000 (respectively). The errors have been corrected in the HTML and PDF versions of the article. *A full list of authors and their affiliations appears at the end of the paper.

Cite

CITATION STYLE

APA

Barrett, J. R., Belij-Rammerstorfer, S., Dold, C., Ewer, K. J., Folegatti, P. M., Gilbride, C., … Zizi, D. (2021, June 1). Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (Nature Medicine, (2021), 27, 2, (279-288), 10.1038/s41591-020-01179-4). Nature Medicine. Nature Research. https://doi.org/10.1038/s41591-021-01372-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free